Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series
2022; Mary Ann Liebert, Inc.; Volume: 33; Issue: 1 Linguagem: Inglês
10.1089/thy.2022.0506
ISSN1557-9077
AutoresKevin J. Contrera, Maria Gule-Monroe, Mimi I. Hu, Maria E. Cabanillas, Naifa L. Busaidy, Ramona Dadu, Steven G. Waguespack, Jennifer Wang, Anastasios Maniakas, Stephen Y. Lai, Julia Diersing, Michael Kwon, Elizabeth G. Grubbs, Vivek Subbiah, Michelle D. Williams, Mark Zafereo,
Tópico(s)Hedgehog Signaling Pathway Studies
ResumoThyroidVol. 33, No. 1 Research LettersNeoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case SeriesKevin J. Contrera, Maria K. Gule-Monroe, Mimi I. Hu, Maria E. Cabanillas, Naifa L. Busaidy, Ramona Dadu, Steven G. Waguespack, Jennifer R. Wang, Anastasios Maniakas, Stephen Y. Lai, Julia Diersing, Michael Kwon, Elizabeth G. Grubbs, Vivek Subbiah, Michelle D. Williams, and Mark E. ZafereoKevin J. Contrerahttps://orcid.org/0000-0002-2570-1706Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.Search for more papers by this author, Maria K. Gule-MonroeDepartment of Neuroradiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.Search for more papers by this author, Mimi I. HuDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.Search for more papers by this author, Maria E. CabanillasDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.Search for more papers by this author, Naifa L. BusaidyDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.Search for more papers by this author, Ramona DaduDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.Search for more papers by this author, Steven G. WaguespackDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.Search for more papers by this author, Jennifer R. WangDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.Search for more papers by this author, Anastasios Maniakashttps://orcid.org/0000-0002-4354-2841Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.Search for more papers by this author, Stephen Y. LaiDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.Search for more papers by this author, Julia DiersingDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.Search for more papers by this author, Michael KwonDepartment of Neuroradiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.Search for more papers by this author, Elizabeth G. GrubbsDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.Search for more papers by this author, Vivek Subbiahhttps://orcid.org/0000-0002-6064-6837Department of Investigational Cancer Therapeutics, and The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.Search for more papers by this author, Michelle D. WilliamsDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.Search for more papers by this author, and Mark E. ZafereoAddress correspondence to: Mark E. Zafereo, MD, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1445, Houston, TX 77030, USA E-mail Address: [email protected]https://orcid.org/0000-0001-7918-9739Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.Search for more papers by this authorPublished Online:13 Jan 2023https://doi.org/10.1089/thy.2022.0506AboutSectionsView articleView Full TextSupplemental MaterialPDF/EPUBView Supplemental Data Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetailsCited byLetter to the Editor: Tumor Lysis Syndrome During Selpercatinib Treatment in a Patient with Medullary Thyroid Cancer Simone De Leo, Matteo Trevisan, Giulia Vanessa Re Sartò, Claudia Moneta, Marta Pirovano, Carla Colombo, Laura Cosmai, and Laura Fugazzola10 August 2023 | Thyroid, Vol. 0, No. 0Neck Surgery for Non-Well Differentiated Thyroid Malignancies: Variations in Strategy According to Histopathology16 February 2023 | Cancers, Vol. 15, No. 4 Volume 33Issue 1Jan 2023 InformationCopyright 2023, Mary Ann Liebert, Inc., publishersTo cite this article:Kevin J. Contrera, Maria K. Gule-Monroe, Mimi I. Hu, Maria E. Cabanillas, Naifa L. Busaidy, Ramona Dadu, Steven G. Waguespack, Jennifer R. Wang, Anastasios Maniakas, Stephen Y. Lai, Julia Diersing, Michael Kwon, Elizabeth G. Grubbs, Vivek Subbiah, Michelle D. Williams, and Mark E. Zafereo.Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series.Thyroid®.Jan 2023.129-132.http://doi.org/10.1089/thy.2022.0506Published in Volume: 33 Issue 1: January 13, 2023Online Ahead of Editing: December 11, 2022PDF download
Referência(s)